Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)

CompletedOBSERVATIONAL
Enrollment

68

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

December 24, 2018

Study Completion Date

December 24, 2018

Conditions
CCR5-tropic HIV-1 Infection
Interventions
DRUG

CELSENTRI® Tablets

"CELSENTRI ® Tablets 150mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage is 300 mg twice daily. Maraviroc must be used in combination with other anti-HIV drugs. The dosage may be adjusted according to co-administered medical products. Maraviroc can be taken with or without food."

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

ViiV Healthcare

INDUSTRY